A Study of LAD603 in Adults With Alopecia Areata
Key facts
- Where
- Omaha, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07311564, who can take part
Where in United States
- Omaha, NebraskaHospital not named in the registryContact: Davide CarluccioTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Almirall, S.A.
- Trial code
- NCT07311564EU 2025-523342-27-00
- Record updated
- 20 May 2026
- Original description
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.Read full original descriptionShow less
A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
Inclusion: Participant is a male or female between 18 and 65 years old at the time of signing the informed consent; Severe to very severe AA criteria:; Greater than or equal to (>=) 50% hair loss of the scalp as measured by SALT without evidence of terminal hair regrowth within 6 months at both the Screening and Baseline (Day 1) visits; Current episode of hair loss lasting at least 6 months and not exceeding 7 years; Participants who are WOCBP or male must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD603 during the study,.
Exclusion: Participant has previous severe adverse reaction to subcutaneously administered medication; Intention to use any concomitant medication that is not permitted by this protocol or failure to undergo the required washout period for a particular prohibited medication; AA, Skin Specific, and Other Inflammatory Diseases; Currently has an active form of other inflammatory skin disease(s) or evidence of skin condition (e.g., psoriasis, seborrheic dermatitis, lupus) at the time of the Screening or Baseline (Day 1) visits that is expected to interfere with the assessment of alopecia areata severity; Other Medical Conditions; Participant has any of the following liver safety laboratory results at Screening; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to (>=) 2.5 × upper limit of normal (ULN); Total bilirubin (TBL) >=1.5 × ULN (TBL >=3 × ULN in participants with Gilbert's syndrome); Alkaline phosphatase (ALP) >=1.5 × ULN; Prior/Concomitant Therapy; Participants have other types of alopecia (including but not limited to traction, scarring alopecia); Participants with "diffuse" type AA.